AKBA (3-O-Acetyl-11-keto-β-boswellic acid)

AKBA (3-O-Acetyl-11-keto-β-boswellic acid) is an inhibitor of Lipoxygenase used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. In practice, this places the compound in experiments that measure inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses in cancer, dna damage / repair, and inflammation models.

By inhibiting Lipoxygenase, AKBA (3-O-Acetyl-11-keto-β-boswellic acid) can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In cancer, dna damage / repair, and inflammation models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Lipoxygenase
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, AKBA (3-O-Acetyl-11-keto-β-boswellic acid) is appropriate when a defined chemical perturbant is needed to connect Lipoxygenase with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, dna damage / repair, and inflammation models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.